BioCentury | Aug 27, 2020
Distillery Therapeutics

Targeting CXCR3, CXCL9 for osteoporosis

...cultures and mouse models.TARGET/MARKER/PATHWAY: CXC chemokine receptor 3 (CXCR3); chemokine CXC motif ligand 9 (CXCL9; MIG...
...National University of Singapore, Singaporeemail: dbswcw@nus.edu.sg. Claire Quang National University of Singapore Chemokine CXC motif ligand 9 (CXCL9) (MIG) CXC...
BioCentury | Sep 11, 2019
Financial News

BioNTech IPO filing says trade war, Hong Kong unrest may be delaying $100M of series B

...would finally bring liquidity for the Strüngmann family, BioNTech’s founding investors. The family office and MIG...
...BioNTech’s shares. An entity associated with co-founder and CEO Ugur Sahin holds almost 19%, while MIG...
BioCentury | Jul 11, 2019
Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

...Cambridge, Mass. Targets 4-1BB (TNFRSF9; CD137) - Tumor necrosis factor receptor superfamily member 9 CXCL9 (MIG...
BioCentury | Feb 1, 2019
Tools & Techniques

TMB needs company

...Chemokine CC motif ligand 5; CD8A (p32; CD8); CMKLR1 (ChemR23) - Chemokine-like receptor 1; CXCL9 (MIG...
BioCentury | Jun 1, 2018
Clinical News

Genentech reports detailed OS data for Tecentriq combo in first-line non-squamous NSCLC

...CI: 0.59, 1.17). Teff measures mRNA expression of PD-L1, chemokine CXC motif ligand 9 (CXCL9; MIG...
BioCentury | Dec 22, 2017
Product Development

Beyond PD-L1 assays

...clinical benefit. Teff quantifies mRNA expression levels for PD-L1, chemokine CXC motif ligand 9 (CXCL9; MIG...
...The Teff panel quantified mRNA expression levels for PD-L1, chemokine CXC motif ligand 9 (CXCL9; MIG...
BioCentury | Dec 15, 2017
Clinical News

Genentech reports detailed data for Tecentriq in first-line NSCLC

...signature expression biomarker. Teff measures mRNA expression of PD-L1, chemokine CXC motif ligand 9 (CXCL9; MIG...
BioCentury | Dec 7, 2017
Clinical News

Genentech reports detailed data for Tecentriq in first-line NSCLC

...signature expression biomarker. Teff measures mRNA expression of PD-L1, chemokine CXC motif ligand 9 (CXCL9; MIG...
BioCentury | Apr 21, 2017
Product R&D

Making marks at AACR

...Macrophage inflammatory protein-1 α CTLA-4 (CTLA4; CD152) - Cytotoxic T-lymphocyte associated protein 4 CXCL9 (MIG...
BioCentury | Mar 16, 2017
Product R&D

Neo wave

...neoantigens Breast cancer; melanoma Phase I Ugur Sahin, Johannes Gutenberg University Mainz Strüngmann Family Office; MIG...
Items per page:
1 - 10 of 59
BioCentury | Aug 27, 2020
Distillery Therapeutics

Targeting CXCR3, CXCL9 for osteoporosis

...cultures and mouse models.TARGET/MARKER/PATHWAY: CXC chemokine receptor 3 (CXCR3); chemokine CXC motif ligand 9 (CXCL9; MIG...
...National University of Singapore, Singaporeemail: dbswcw@nus.edu.sg. Claire Quang National University of Singapore Chemokine CXC motif ligand 9 (CXCL9) (MIG) CXC...
BioCentury | Sep 11, 2019
Financial News

BioNTech IPO filing says trade war, Hong Kong unrest may be delaying $100M of series B

...would finally bring liquidity for the Strüngmann family, BioNTech’s founding investors. The family office and MIG...
...BioNTech’s shares. An entity associated with co-founder and CEO Ugur Sahin holds almost 19%, while MIG...
BioCentury | Jul 11, 2019
Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

...Cambridge, Mass. Targets 4-1BB (TNFRSF9; CD137) - Tumor necrosis factor receptor superfamily member 9 CXCL9 (MIG...
BioCentury | Feb 1, 2019
Tools & Techniques

TMB needs company

...Chemokine CC motif ligand 5; CD8A (p32; CD8); CMKLR1 (ChemR23) - Chemokine-like receptor 1; CXCL9 (MIG...
BioCentury | Jun 1, 2018
Clinical News

Genentech reports detailed OS data for Tecentriq combo in first-line non-squamous NSCLC

...CI: 0.59, 1.17). Teff measures mRNA expression of PD-L1, chemokine CXC motif ligand 9 (CXCL9; MIG...
BioCentury | Dec 22, 2017
Product Development

Beyond PD-L1 assays

...clinical benefit. Teff quantifies mRNA expression levels for PD-L1, chemokine CXC motif ligand 9 (CXCL9; MIG...
...The Teff panel quantified mRNA expression levels for PD-L1, chemokine CXC motif ligand 9 (CXCL9; MIG...
BioCentury | Dec 15, 2017
Clinical News

Genentech reports detailed data for Tecentriq in first-line NSCLC

...signature expression biomarker. Teff measures mRNA expression of PD-L1, chemokine CXC motif ligand 9 (CXCL9; MIG...
BioCentury | Dec 7, 2017
Clinical News

Genentech reports detailed data for Tecentriq in first-line NSCLC

...signature expression biomarker. Teff measures mRNA expression of PD-L1, chemokine CXC motif ligand 9 (CXCL9; MIG...
BioCentury | Apr 21, 2017
Product R&D

Making marks at AACR

...Macrophage inflammatory protein-1 α CTLA-4 (CTLA4; CD152) - Cytotoxic T-lymphocyte associated protein 4 CXCL9 (MIG...
BioCentury | Mar 16, 2017
Product R&D

Neo wave

...neoantigens Breast cancer; melanoma Phase I Ugur Sahin, Johannes Gutenberg University Mainz Strüngmann Family Office; MIG...
Items per page:
1 - 10 of 59